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A B S T R A C TObjectives: To assess patients’ preferences and estimate willingness
to pay (WTP) for gastroesophageal reflux disease (GERD) treatments.
Method: Patients were randomly selected from a multicenter clinical
study to participate in the discrete choice experiment (DCE) survey.
Relevant treatment attributes were identified through literature
review, clinical expert consultation, and focus groups. The DCE
included 14 choice tasks composed of six attributes, three treatment
profiles, and a ‘‘none’’option considering orthogonality, D-efficiency,
and level balance, while keeping patient response burden reasonable.
Individual-level preferences and WTP were estimated by aggregate-
level conditional logit and hierarchical Bayes analyses. Results: Our
sample of 361, drawn from a clinical trial, had a mean age of 57 years,
were primarily women (53%), and rated their GERD symptoms as mild/
moderate (31%) and moderately severe/severe (7%). Most important
attributes of GERD treatment were (in order) as follows: avoiding side
effects, sleeping discomfort, daytime discomfort, dietary changes,see front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.01.007
a.dabrowski@optum.com.
ondence to: Dominika Dabrowski, 5500 North Servimedication cost, and treatment frequency. Simulations found that
patients are willing to pay an additional US $36 to reduce susceptibility
to side effects from moderate to mild or to decrease the frequency of
sleeping discomfort. Patients 65 years or older were willing to pay less
for daytime discomfort relief, while women would pay more to avoid
sleeping discomfort. Conclusions: Key factors concerning patients with
GERD and their preference for treatment features to control GERD
symptoms were confirmed. A DCE estimated WTP by GERD sufferers
for relief from symptoms and avoidance of side effects using relevant
treatment costs. These findings may help guide clinical treatment
decisions for individual patients to improve GERD symptom control.
Keywords: conjoint analysis, discrete choice experiment, gastro-
esophageal reflux disease, stated preferences, willingness-to-pay.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Gastroesophageal reflux disease (GERD) is the most prevalent
acid-related disorder in Western populations, with heartburn and
regurgitation as the predominant symptoms [1,2]. Approximately
25% of the population suffers from these symptoms at least
monthly and 5% have daily heartburn [3]. Worldwide, more than
720 million prescriptions have been written for proton pump
inhibitors (PPIs) [4]. In the United States, the number of dispensed
prescriptions for PPIs increased by 28% from 2002 to 2009 [5].
In Canada, more than US $670 million is spent on PPIs and
histamine H2 receptor antagonist therapy each year [1]. Most
patients with GERD require long-term therapy; however, when
drug therapy is discontinued, about 80% of patients with GERD
experience symptom relapse after 6 to 12 months [2].
Patient survey results indicate that people with GERD experi-
ence lower health-related quality of life than the general pop-
ulation and often demonstrate health-related quality-of-life
impairments comparable to those seen in other chronic diseases
such as asthma, heart failure, angina pectoris, and cancer, eventhough related mortality rates are low [6,7]. Furthermore, GERD is
associated with decreased productivity and lost workdays from
related symptoms. A 2005 Canadian study found that employed
patients with moderate to severe symptoms lost 6.7 hours of
work time each week because of GERD symptoms [8]. Poor
medication compliance is a significant barrier to the effective
management of GERD, and selecting medications that offer the
best symptom relief for an individual patient is critical to
encourage continued adherence to long-term therapy.
PPIs are the most effective therapy for GERD, demonstrating
significantly improved effectiveness (time to symptom relief and
degree of healing) compared with over-the-counter antacids or H2
receptor antagonists in patients with frequent or severe GERD
symptoms [9]. Current guidelines recommend that treatment
with PPIs should be continued on a long-term basis at the lowest
dose sufficient to control symptoms [1].
Six PPIs were licensed in Canada at the time of the study:
lansoprazole, pantoprazole, rabeprazole, esomeprazole, omepra-
zole, and generic omeprazole [9]. A 2011 Canadian estimate for a
30-day full-dose supply of PPIs on formularies, not includingSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ce Road, Suite 501, Burlington, ON L7L 6W6, Canada.
Table 1 – Attributes and levels included in the
discrete choice survey.
No. Attributes Levels
1. Medication cost per
month
 $3 per month
 $30 per month
 $50 per month
 $70 per month
2. When you take your
GERD medication
 Twice daily
 Once daily
 1 pill when you think acid
reflux might occur
 1 pill after acid reflux begins
3. Diet changes  Must radically change your
diet (e.g., completely
eliminating choices of food,
eating much less food,
changing the time of day
when you eat, and so on)
 Must eliminate eating some
foods and beverages you like
 Must reduce eating some
foods and beverages you like
 You are able to eat what you
ate before GERD
4. Daytime discomfort
due to acid reflux
and heartburn
 4 or more episodes of acid
reflux during the day
 1 to 3 episodes of acid reflux
during the day
 1 to 3 episodes of acid reflux
during a week
 1 to 3 episodes of acid reflux
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 8 8 – 5 9 8 589markup or dispensing fees, ranged from US $10 [10] to US $64 [11]
per month [12]. (During the time of this study, the Canadian
dollar ranged in value from US $0.97 to US $1.03.)
Willingness to pay (WTP) is an indicator of the monetary value
that people would pay for a product or service. In this study, we
define marginal WTP as the price increment that moves con-
sumers from preferring one treatment over another to being
indifferent between purchasing the two treatments. A patient’s
WTP for a medication will depend on several factors, including
the drug’s effectiveness, side effects, dosing, tolerability, conven-
ience, and the patient’s ability to pay [13–19]. Discrete choice
experiments (DCEs) have increasingly been used in health care to
determine patients’ treatment preferences, as well as WTP as an
indication of preferences [20–26]. DCEs are considered to be
advantageous over contingent valuation questions for assessing
WTP values because marginal estimates are obtained for each of
the treatment attributes [27]. DCEs facilitate the estimation of
WTP values for any theoretical combination of the attribute
levels, although illogical or ill-advised combinations may limit
the range of combinations somewhat in practical applications
[17].
One US study [18] used DCE trade-offs among treatment
options to estimate the WTP for a prescription medication that
offers complete symptom relief from GERD. Patients placed more
importance on the degree of symptom relief than on the occur-
rence of side effects, time to relief, and increased out-of-
pocket costs.
This study of patient preferences was designed to assess
GERD patients’ WTP for a prescription medication that offers
improved symptom relief; the findings are expected to help guide
clinicians when selecting the best GERD treatment for their
patients. A few other studies estimated utilities and WTP by
using other methods. Typically, those other studies did not
include the range of attributes used in this research. A study by
Kartman et al. [28] used variations in only symptom severity to
measure utilities.during a month
 No episodes of acid reflux
during the daytime
5. Sleeping discomfort
due to acid reflux
and heartburn
 4 or more episodes of acid
reflux during a night’s sleep
 1 to 3 episodes of acid reflux
during a night’s sleep
 1 to 3 episodes of acid reflux
during your sleep over a
week
 1 to 3 episodes of acid reflux
during your sleep over a
month
 No acid reflux during
your sleep
6. Side effects  No side effects
 Mild side effects
 Moderate side effects
 Severe side effects
GERD, gastroesophageal reflux disease.Methods
Survey Participants
Patients were selected randomly from 17 clinical trial sites across
Canada that was part of a cross-sectional multicenter study
(Retrospective ANalysis of GErd) of symptom burden and clinical
management in GERD [29]. The patients, who were Canadians,
aged 18 years or older, diagnosed with GERD for 6 or more
months, and under active treatment with prescription medica-
tion for the disease, were asked to complete the discrete choice
questionnaire at the clinical trial site. The trial ran from January
14, 2008, to May 30, 2008.
Defining Attributes for the Discrete Choice Survey Instrument
We identified relevant attributes for the discrete choice survey
instrument through a literature review [1–7], consultation with
clinical experts and gastrointestinal medical advisors, and two
focus groups of 10 participants each who met the clinical trial
requirements and were comfortable participating in group dis-
cussions. Past focus group participation was not an exclusion
criterion. By using a structured interview guide, mutually exclu-
sive, comprehensive, and quantifiable attributes and attribute
levels relevant to prescription medication use for patients with
GERD were identified through direct analysis of the focus group
transcripts (Table 1).
This discrete choice survey was designed to consider the
trade-offs among substantive disease-related attributes andtreatment benefits. Consequently, brand names were not
included in the choice options; that is, this was an unlabeled
study [30]. The cost of PPIs for the survey, not including markup
or dispensing fees, was calculated according to the public payer
pricing from Ontario in 2008, and ranged from almost US $10 to
US $65 per month, and a median of US $30 per month. The levels
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payment tiers of PPIs in Canada to reflect an expected range of
what Canadian patients would be willing to pay plus US $3 per
month to represent co-pay fees for those on drug plans. Infor-
mation about markup and dispensing fees can be obtained from
the Government of Canada Patented Medicine Prices Review
Board [31].Discrete Choice Survey Design
Each choice alternative included six attributes: out-of-pocket
medication cost per month, when medication was to be taken,
diet changes, daytime discomfort due to GERD, sleeping discom-
fort due to GERD, and side effects of GERD medication. Each
attribute included four or five levels (Table 1). The levels of all
attributes were at least ordinal with the levels of diet changes
and side effects being descriptive phrases whereas the levels of
the other four attributes contained numerical descriptors. The
attributes and their levels were closely matched to alternative
treatments available and to subjects’ treatment desires as based
on the focus groups and other background information. Diet
changes, daytime discomfort, and sleeping discomfort due to
GERD were the key measures of efficacy of the treatment.
The nature and form of the DCE component of the question-
naire were explained in detail to respondents in a two-page
introduction to the DCE. For example, the side-effects attribute
was explained as ‘‘Sometimes side effects occur as the result of
GERD medication. These side effects can include nausea, diar-
rhea, stomach upset and headaches.’’ Those levels were
explained in more detail in the DCE introduction, for example,
‘‘Mild side effects: easily tolerated, causes minimal discomfort
and does not interfere with everyday activities.’’
The survey contained a total of 14 choice tasks each with
three choice alternatives—12 were random choice tasks plus 2
fixed tasks to evaluate validity and internal reliability [32].Medication cost $50 per month
When you take your GERD medication Once daily
Diet changes
Must radically change your
diet
Daytime discomfort due to acid reflux &
heartburn (GERD)
1 to 3 episodes of acid 
reflux during the day
Sleeping discomfort due to acid reflux &
heartburn (GERD)
No acid reflux during sleep
Side effects  for example nausea,
diarrhea, stomach upset, headaches, and
so on
Mild side effects
Yes
No
Given what you know about your condition and GERD treatments, wou
Cho
If these were your only options for a GERD medication treatment, a
choose to b
Fig. 1 – GERD, gastroesophA ‘‘dual response none’’ question [33,34] was inserted after each
DCE choice task to determine whether patients would actually
buy the GERD medication that had just been chosen. (One
representative choice task is shown in Fig. 1.) Each patient had
the opportunity to choose one of the three treatment profiles and
then indicate whether that treatment would actually be bought
or not. Subjects were not asked to choose one of the three
treatment options versus their current treatment because the
purpose was to identify ideal treatments rather than estimate
shares among competing alternatives. The dual response none
question allowed subjects to select responses that indicated the
alternatives offered in the choice task were not as good as their
current treatment.
All survey questions were programmed into Sawtooth Soft-
ware’s SSI Web application for designing and executing Internet
surveys. Sawtooth Software implements randomized experimen-
tal designs that are close to optimally efficient [35]. Sawtooth
Software’s Advanced Design Test, operating in the complete
enumeration mode, was used to test the quality of the design
for orthogonality, D-efficiency, and level balance, while keeping
respondent burden reasonable. Complete enumeration considers
all possible permissible designs and chooses each so as to produce
the most nearly orthogonal design for each respondent [36].
The choice alternatives within each choice task are kept as
different as possible to achieve minimal overlap. This procedure
of randomized designs may be slightly less efficient than fully
orthogonal designs but provides for estimating all interaction
effects in addition to main effects [37]. The quality of the
experimental design was evaluated by comparing the estimated
standard errors (SEs) for each attribute level, except for the base
levels, to the corresponding SEs if the design were perfectly
orthogonal. The design for this study produced estimated actual
SEs that were at least 97.4% of what they would have been if the
design were orthogonal, with 15 of the 26 efficiencies being above
99.1%. This is considered to be a highly efficient design. An$3 per month $70 per month
Twice daily 1 pill after acid reflux begins
Must eliminate eating some 
foods & beverages you like
Must reduce eating some 
foods & beverages you like
1 to 3 episodes of acid 
reflux during a month
4 or more episodes of acid
reflux during the day
4 or more episodes of acid
reflux during a night's sleep
1 to 3 episodes of acid 
reflux during your sleep
over a month
Severe side effects No side effects
ld you really buy the GERD medication you chose above or not?
ose by clicking one of the buttons below:
nd this is the cost you would actually pay, which would you
uy?
ageal reflux disease.
Table 2 – Demographic and socioeconomic charac-
teristics (n ¼ 361).
Age (y)
Mean  SD 57  16
Minimum–maximum 19–94
Sex, n (%)
Women 190 (53)
Total household income, n (%)
$0–$49,999 160 (44)
$50,000–$99,999 106 (30)
$100,000þ 62 (17)
Missing response or not applicable 33 (9)
Types of health insurance beyond your provincial
health plan, n (%)
All prescription drug costs, including
dispensing fee
105 (29)
Some portion of prescription drug costs 148 (41)
Some portion of prescription drug costs up to a
specific amount, and all prescription drug
costs above that amount
27 (8)
Not sure 47 (13)
Missing response 34 (9)
Current employment status, n (%)
Full-time or part-time employed 160 (44)
Retired/long-term sick leave 158 (44)
Other 43 (12)
Average symptom severity as measured by the
Reflux Disease Questionnaire, n (%)
Did not have 217 (60)
Very mild to moderate 112 (31)
Moderately severe to severe 25 (7)
Missing response 7 (2)
Note. Values shown are n (%), unless otherwise indicated.
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answers were simulated. The analysis was conducted by using
conditional logit (CL) and all the 27 main effects P values were
less than 0.05, with 16 being below 0.035 and 10 between 0.035
and 0.04. The general rule-of-thumb is that the main effects SEs
be approximately equal and be less than or equal to 0.05 [38]. This
indicated that sufficiently accurate estimates would likely result
from the actual survey.
Survey Administration
The discrete choice survey was pretested in a convenience
sample of six health services researchers. The final DCE survey
was administered by pen and paper to 361 patients in the
Retrospective ANalysis of GErd clinical trial. Each of the 17 sites
in the study received two paper copies of each of the 10 distinct
versions of the survey and administered the survey versions
randomly.
A formal sample size calculation for the DCE survey was not
undertaken because this was part of a clinical trial. For a DCE
study, a sample size of 300 to 500 subjects is generally considered
adequate [39] and this study met that specification.
Analytic Methodology
Missing data
Analysis included patients who had completed all the DCE choice
tasks. Multiple imputation of missing values was performed for
some of the non-DCE variables that were included as covariates
in the subgroup analysis (Reflux Disease Questionnaire [12 ques-
tions with less than 1% missing], Patient Profile Questionnaire [12
questions with less than 10% missing], and WTP Questionnaire
[10 questions with 10% or less missing]) using Amelia II [40].
Analysis of DCE choices
Our analysis of the choice data estimated part-worth, or marginal,
utilities (PWUs) [26,39,41] that quantify the appeal of each attribute
level and leads to measures of the importance of each attribute in
influencing respondent choices. CL analysis was performed as a
first-level analysis of the choice data. We used hierarchical Bayes
(HB) analysis to minimize bias from the independence of irrelevant
alternatives inherent in CL and estimate preference coefficients at
the individual respondent level [41–43].
The reliability of the survey responses for the DCE choice tasks
was examined by analyzing the accuracy of predicting the fixed
choice tasks that were not included in the main analysis. All
statistical tests used a 5% level of risk to test statistical significance.
Analysis of variance, multivariate analysis of variance, and
independent sample t tests were used to explore whether signifi-
cant differences existed in preference coefficients among sub-
groups formed by demographic variables and behavioral and
attitudinal covariates. We investigated the following covariates for
inclusion in the final analysis— disease severity, level of control and
disease symptoms, productivity loss, and activity impairment—in
addition to subject demographic variables (i.e., age, income, etc.).
We measured the influence of the attributes in driving the
selection among treatment choices and estimated respondents’
WTP for attribute-level benefits and various treatment configu-
rations using simulations and sensitivity analyses [44,45]. Sce-
narios composed of two treatment profiles each were defined
where all attribute levels were the same, including cost, except
for one attribute where two different levels were used. The cost of
the more preferred treatment was increased in the simulation
until it was equally preferred to the less preferred treatment,
with the marginal WTP estimated as the difference in cost
between the beginning, equal cost, and ending, equal preference,
positions.Software
Sawtooth Software SSI Web, a specialized software package for
DCE survey design and analysis, was used to design the study
and produce the questionnaires while the DCE analysis using CL
and the WTP simulations were executed with Sawtooth Software
Advanced Simulator (SMRT 4.18.2). SAS 9.1.3 and Microsoft Excel
2003 were used for summary tables; SPSS v16 was used for the
multivariate analysis. Respondent-level PWUs were estimated by
using HB analysis in Sawtooth Software CBC/HB. Only the HB
coefficients were used beyond the most basic analysis. The R
package Amelia II [40] with a bootstrap Expectation-
Maximization-Bayesian algorithm [46] was used for the multiple
imputation of missing values for non-DCE analysis variables. R
was used for data manipulation and some of the multivariate
analysis.Results
Of the 366 clinical trial patients who attended the first protocol
visit, 361 completed the DCE survey fully. More than half of the
patients (53%) were women, and the sample mean age was 57
years (Table 2). A large proportion (41%) paid some portion of
their prescription drug costs not covered by their provincial
health insurance. Most patients (60%) did not have GERD symp-
toms in the week before taking the survey. One-third (31%) rated
their GERD symptoms as mild to moderate, and a small number
(7%) rated their GERD symptoms as moderately severe to severe
using the Reflux Disease Questionnaire (Table 2).
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fixed-choice tasks; one appeared as the fifth task and the other
as the twelfth. The two choice tasks were identical except that
the order positions of the alternatives were shuffled. The w2
statistic was 3.53 and indicated that the responses to the two
tasks were not significantly different (5% level of risk).
There appeared to be no position bias among the choice
alternatives in that 33% of the choices were for the alternative
in the leftmost position, 34% for the center option, and 33% for
the rightmost alternative. w2 analysis of the counts data showed
that the PWUs for all attributes were significantly nonuniformly
distributed (all significant at o0.01 level of risk).
Both the CL estimation of PWUs and the HB estimates
confirmed our a priori hypotheses that patients would prefer
GERD treatment options that offer the greatest amount of symp-
tom relief (day and night) (HB PWU of 35.2 and 51.4, respectively),
without any side effects (PWU ¼ 76.8), and without having to alter
their diet from pre-GERD days (PWU ¼ 23.5). The averaged HB
PWUs and 95% confidence limits are graphed in Figure 2.
Once-daily dosing of the treatment is most preferred (PWU ¼
10.6). The monthly cost of GERD treatment was analyzed as being
categorical; Johnson et al. [47] rejected linearity in the cost
function. The PWU for the US $3 cost (mean ¼ 16.8, SE ¼ 2.67)
was not significantly different (Pr 0.05) from the PWU for the US
$30 cost (mean ¼ 20.06, SE ¼ 1.81). This nonsignificant directional
anomaly may simply be statistical or it could represent an effect of
price-imputed quality at the low price end where perhaps patients
were not confident of the quality of such a low-priced treatment at
US $3 per month. The most important attribute of GERD treatment
was avoiding side effects, followed by sleeping discomfort,
daytime discomfort, and dietary changes. Time when GERD med-
ication was taken and medication cost were the least important
attributes.
Two simulations were conducted to estimate the range of the
dual response none answers. One of the simulations pitted the
two best treatment configurations against each other, and theFig. 2 – GERD, gastroesophother included the two worst treatments, as estimated using the
PWU values and results from other simulations. For the com-
petition between two so-called best treatments, 9.6% indicated
that they would not buy the treatment they chose in the choice
exercise. When the two worst treatments were simulated,
approximately 90% of respondents indicated that they would
not actually buy the treatment that they had chosen. This range
appears to be reasonable considering the competitive context of
the simulations and the randomness built into the randomized
first choice method for executing the simulations.
The subgroup analyses (Table 3) found statistically significant
differences among the importance of attributes based on age,
sex, employment status, and income (P r 0.01 for Wilk’s l F for
each of those demographic variables). Univariate tests suggest
that those who had lower incomes placed greater importance on
medication cost than did those having higher incomes (P ¼ 0.000
for F) while those having higher incomes placed greater impor-
tance on necessary dietary changes than did those with lower
incomes (P ¼ 0.002 for F).
We discovered many significant differences in the PWUs
among groups (Table 4). For example, those with lower incomes
appeared to significantly prefer the US $3 monthly costs of GERD
treatments compared with those with higher incomes (P ¼ 0.003
for F) and significantly disprefer the US $70 monthly cost over
those with higher incomes (P ¼ 0 .001 for F). Those who had
higher incomes seemed to have significantly lower preferences
for making radical changes in their diets than did those with
lower incomes (P ¼ 0.000 for F) while those higher income
individuals tended to have significantly higher preferences for
reducing the eating of some foods and beverages they desired
than did those in lower-income levels (P ¼ 0.000 for F).
Other significant differences among preferences for levels of
the attributes for demographic, attitudinal, and behavior dimen-
sions are shown in Table 4 where multivariate analysis of
variance F (Wilk’s l) tests for differences over the several levels
of each attribute and Brown-Forsythe F tests for differences overageal reflux disease.
Table 3 – Attribute importance differs among some subgroups.
Attribute Importance by
subgroup
F Comments
Medication cost per month Annual household
income
7.388y Cost more important to those with lower incomes
Age 29.514y Older subjects find cost more important
Employment status 16.263y Cost more important to those retired/long-term sick
leave
Dietary changes Annual household
income
3.738z Dietary changes more important to those with higher
incomes
Age 3.989y Younger subjects find dietary changes more important
Sleeping discomfort due to acid reflux and
heartburn
Age 12.845y Younger subjects find relief from sleeping discomfort
more important
Sex 11.434y Relief from sleeping discomfort more important to
women
Daytime discomfort due to acid reflux and
heartburn
Age 18.290y Younger subjects find relief from daytime discomfort
more important
 Brown-Forsythe F.
y Significance r0.001.
z Significance r0.01.
y Significance r0.05.
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for age, income, employment status, sex, education, lost work
productivity, degree of control as measured by the Proton pump
inhibitor Acid Suppression test, general practitioner visits for
GERD, disease severity, insurance coverage, quality of health
improvement, and satisfaction with main GERD medication.
The overall effects for some covariates were significant—there
were several significant differences found for age, income,
employment, sex, and education. For example, those younger
than 65 years had significantly greater dispreference (lower
PWUs) for one to four and one to three episodes per day, while
that group had higher preferences for the less frequent incidence
levels. Individual-level tests also found many nonsignificant
differences among covariate subgroups for attributes. Levels of
insurance coverage, general practitioner visits for GERD, disease
severity, quality-of-life improvement, and satisfaction with their
main GERD medication were not found to be related to prefer-
ences for attributes.WTP Estimates
Simulation analyses suggested that patients were willing to pay an
incremental US $36 per month to avoid moderate side effects in
favor of mild side effects and incur a marginal payment of US $29
to move to a state of no side effects at all from having mild side
effects. (Table 5 shows the marginal WTP [MWTP] estimates and
95% confidence limits, which provided a range within which the
real WTP likely resides.) These MWTP levels seem reasonable and
are in line with the relative differences between PWUs for side
effects (Fig. 2). The MWTP for relieving patients of severe side
effects and having moderate side effects would have caused us to
extrapolate beyond the US $70 upper limit of the cost attribute,
which we chose not to do because of the nonlinear nature of the
cost utility function. Respondents were marginally willing to pay
US $36, and possibly as high as US $44.16 at the highest confidence
limit, to decrease their sleeping discomfort from one to three
episodes per night to one to three episodes per week, US $16 to
decrease their sleeping discomfort from one to three episodes per
week to one to three episodes per month, and US $24 to move
from one to three episodes per month to no sleep episodes. The
MWTP was not calculated for moving from four or more episodesper night to one to three episodes per night because of having to
extrapolate outside of the range of survey data.
Given the somewhat broader range of PWUs and greater
importance of sleeping discomfort over daytime discomfort,
patients’ marginal WTP was slightly less for relief from daytime
discomfort caused by GERD: US $28 to move from four or more
episodes per day to one to three episodes per day, US $28 for relief
from one to three episodes per day in favor of one to three
episodes per week, US $12 for one to three episodes per month
rather than one to three episodes per week, and US $14 to move
to no daytime episodes from one to three episodes per month.
While diet changes were relatively less important than side
effects, sleeping, and daytime discomfort, the PWUs for radically
changing your diet and eliminating some foods you like were so
different as to extend the MWTP calculation beyond the range of
data and was not calculated. By inference from the PWUs,
respondents were eager to avoid any radical changes to their
diets. The MWTP was US $9 for moving from eliminating some
foods you like to reducing some foods and beverages you like and
US $9 for being able to eat what you ate before GERD to reducing
eating some foods and beverages.
Dosing was the least important of the six attributes. The
largest MWTP was US $15 between dosing levels of twice daily to
once daily (more preferred). The MWTP to move from twice-daily
dosing to taking the GERD medication when GERD might occur
(more preferred) was US $3, the lowest estimated MWTP overall.
Clearly, the MWTP for GERD treatment that simultaneously
avoids severe side effects, reduces sleeping and daytime discom-
fort below four or more episodes per day, and does not make
patients radically change their diets would be higher than the
estimates provided. We have not calculated that value because it
is outside of the range of cost levels included in the survey.
Patients older than 65 years were less willing to pay for reduced
daytime discomfort, while avoiding sleeping discomfort was
more important to women than to men.Discussion
Our findings indicate that patients’ choices of GERD treatment are
impacted most strongly by side effects, then by disturbances
during sleep, disturbances during the day, dietary changes,
Table 4 – Multivariate F (Wilk’s k) for each attribute/Univarite Brown-Forsythe F for each attribute level
Attributes Part-
Worth
Utilities,
Total
(n¼361)
Age Income
(hh)
Employ-
ment
Sex Educa-
tion
Lost
Work
Produc-
tivity
PASS
test
result
GP
Visits
for
GERD
Symp-
toms
during
past
week
Insur-
ance
cover-
age
Quality
Health
Improve-
ment
Satis-
faction
with
main
GERD
medica-
tion
Monthly cost of treatment 7.501 1.956y 2.364y 2.918y 2.291y 1.796 0.583 0.053 0.787 1.144 0.859 0.540
$3 per month 16.80 8.462z 3.680z 3.668y 0.548 4.703y 0.407 1.043 0.107 1.032 2.048 1.071 0.479
$30 per month 20.06 10.111z 0.794 2.702 7.051z 4.687y 3.901 0.193 0.034 0.247 0.159 0.914 0.464
$50 per month 8.48 5.342y 1.747 1.016 0.589 6.917 3.047 0.324 0.159 0.942 0.686 0.041 1.358
$70 per month 28.38 16.450 4.074 7.515 5.499y 5.388z 1.621 1.398 0.052 0.006 0.752 0.071 0.254
When GERD medication taken 1.212 1.061 1.275 1.196 1.454 0.595 1.669 1.960 0.404 0.825 1.924 0.386
Twice daily 6.96 3.683 0.657 1.500 1.447 0.369 1.696 2.340 3.332 0.362 0.204 1.716 0.514
Once daily 10.65 0.083 1.085 1.233 1.315 1.445 0.008 0.003 0.001 0.050 1.278 0.035 0.530
1 pill when you think acid reflux might occur 4.59 0.250 0.555 1.482 2.239 3.742y .0384 3.241 3.122 1.017 0.811 0.434 0.504
1 pill after acid reflux begins 0.91 0.578 1.544 0.384 1.070 1.719 0.001 0.109 0.079 0.039 1.227 3.356 0.122
Changes to diet 7.107 2.429y 2.590y 1.449 2.715y 4.007z 2.802y 5.010z 2.779y 1.236 0.069 0.549
Must radically change your diet 42.12 8.120z 5.104 3.487y 0.955 2.361 11.714 1.207 2.292 3.324 2.919y 0.006 0.783
Must eliminate eating some foods & beverages you like 5.34 4.031y 2.110 1.171 0.009 0.873 3.041 2.018 0.037 0.016 2.162 0.001 0.108
Must reduce some foods & beverages you like 13.32 18.627 6.035 6.81 0.005 6.041z 11.357 1.625 9.611z 6.388y 1.940 0.079 0.378
You can eat what you ate before GERD 23.46 0.121 1.335 0.825 2.747 0.466 3.992y 3.647 0.252 1.969 1.751 0.002 0.920
Daytime discomfort due to GERD 8.485 1.308 3.194 1.149 2.302y 0.883 1.113 2.031 0.328 1.107 1.292 0.455
4 or more episodes of acid reflux duing the day 43.97 27.051 2.165 5.934z 1.139 2.545 2.993 0.006 2.607 0.014 0.239 0.927 0.028
1–3 episodes of acid reflux during the day 18.30 15.541 0.911 2.311 3.950y 1.893 1.215 0.534 0.512 0.988 0.636 5.238y 0.375
1–3 episodes of acid reflux during the week 8.22 15.935 1.222 7.485 1.340 3.839y 2.005 0.476 2.824 0.000 0.828 0.172 0.126
1–3 episodes of acid reflux during the month 18.81 39.181 3.266z 9.228 2.607 6.131z 3.066 0.243 0.200 0.157 0.424 3.197y 0.078
No episodes of acid reflux during the daytime 35.24 6.304y 0.665 0.215 1.115 0.018 1.148 2.097 0.015 0.409 1.613 1.591 0.402
Sleeping discomfort due to GERD 5.686 1.704y 2.675z 3.516z 1.330 0.261 1.894 1.251 1.140 1.358 0.236 0.521
4 or more episodes of acid reflux during a night’s sleep 60.70 19.883 2.46y 4.882z 7.441z 2.538 0.489 4.690y 1.174 2.016 0.277 0.086 1.768
1–3 episodes of acid reflux during a night’s sleep 24.16 8.274z 0.964 0.844 5.107y 0.498 0.460 3.480 0.054 0.962 0.707 0.068 0.628
1–3 episodes of acid reflux during your sleep over a
week
8.47 12.553 3.953z 3.488y 0.430 1.226 0.053 0.074 2.732 0.452 0.248 0.183 0.173
1–3 episodes of acid reflux during your sleep over a
month
25.00 17.718 1.246 4.418y 3.658 0.971 0.342 2.384 0.035 1.945 0.294 0.006 1.566
No acid reflux during sleep 51.39 4.664y 1.116 1.163 13.381 0.679 1.100 9.420z 0.173 2.871 0.239 0.107 0.847
Side effects 4.382y 1.912y 1.476 1.651 3.455z 1.987 1.806 0.951 2.123 0.297 1.143 1.470
No side effects 76.76 0.914 1.995 0.306 0.428 3.179y 1.435 0.799 0.940 0.219 0.195 2.629 0.652
Mild side effects 44.03 2.446 0.799 2.184 0.000 5.585z 2.987 0.743 0.817 1.578 0.573 0.125 0.866
Moderate side effects 5.66 6.594y 1.947 0.555 0.607 0.179 2.732 0.013 2.239 0.178 0.141 4.269y 2.584
Severe side effects 126.45 2.186 2.333y 3.034 1.253 8.871 0.862 0.189 0.146 0.023 0.508 0.098 0.637
Note. Age (o65, 65r); Income (five categories); Employment (three categories); Sex (M, F); Education (three categories); Lost Work Productivity (Yes, No); PASS test (Fail, Pass); GP Visits for GERD
(No, Yes); Symptoms during past week (1 / wk, 2 þ / wk); Insurance coverage (three categories); Quality of Health Improvement (Yes, No); Satisfaction (three categories).
F, female; GERD, gastroesophageal reflux disease; GP, general practitioner; M, male; PASS, Proton pump inhibitor Acid Suppression.
* (sigr 0.001)
y (sig r 0.05)
z (sig r 0.01).
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Table 5 – Willingness to pay for increased benefits on each attribute.
Attribute Comparisons between attribute benefits Incremental
WTP (US $/
month)
Lower
confidence
limit ($)
Upper
confidence
limit ($)Better Worse
When you take your GERD
medication
Once daily After GERD begins 8 4.50 12.22
Once daily Twice daily 15 12.02 19.39
Once daily When GERD might
occur
12 8.27 16.56
When GERD might
occur
Twice daily 3 0.70 6.45
After GERD begins Twice daily 8 4.64 10.79
After GERD begins When GERD might
occur
4 1.44 7.99
Diet changes Reduce eating some
foods and
beverages
Eliminate eating
some foods and
beverages
9 6.74 11.75
Eat what you ate
before GERD
Reduce eating some
foods and
beverages
9 7.01 11.26
Daytime discomfort due to
acid reflux and
heartburn
1–3 episodes/d 4 or more episodes/d 28 21.93 34.01
1–3 episodes/wk 1–3 episodes/d 28 20.71 36.00
1–3 episodes/mo 1–3 episodes/wk 12 9.15 14.84
No daytime
episodes
1–3 episodes/mo 14 11.75 17.72
Sleeping discomfort due to
acid reflux and
heartburn
1–3 episodes/wk 1–3 episodes/night 36 28.26 44.16
1–3 episodes/mo 1–3 episodes/wk 16 12.93 19.97
No sleep episodes 1–3 episodes/mo 24 17.72 30.95
Side effects Mild side effects Moderate side effects 36 28.62 43.95
No side effects Mild side effects 29 21.33 36.19
Note. Incremental WTP above a base of $30.
GERD, gastroesophageal reflux disease; WTP, willingness to pay.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 8 8 – 5 9 8 595monthly cost, and dosing. GERD patients’ MWTP appear to be
considerably beyond what is covered by public health insurance
for avoiding side effects from treatment and avoiding GERD
symptoms they experience during the daytime or while sleeping.
The absence of side effects was more important than either relief
of discomfort during sleeping or in the daytime. And while dietary
changes are least important overall, patients’ MWTP for not
having to radically change their diets appears to be substantial.
Attribute importance to patients’ choices of treatments varied
by age, sex, employment status, and income. We found attribute
preference differences among subgroups of patients based on
income, age, sex, employment status, disease severity, and
several other variables. For example, dietary changes were more
important to younger subjects and those with higher incomes.
This information can guide physicians to select the most appro-
priate therapy for their individual patients on the basis of patient
characteristics.
In several areas of health care, DCEs have been used to inform
decision making to optimize treatment strategies with the intent
of improving treatment adherence [19]. We found only two WTP
studies of GERD treatment, and neither was in the Canadian
setting. One group of investigators in the United States assessed
the WTP for GERD, but did not evaluate the WTP for symptom
relief [48]. The only attribute they evaluated was diagnostic
certainty. A second US study by Kleinman et al. [18] assessed
WTP for a prescription medication that offers complete symptom
relief from GERD. They found that respondents were willing to
pay US $182 additional per month (out of pocket) to resolve
symptoms, decrease time of onset to relief, and have no side
effects. Those patients placed more importance on the degree ofsymptom relief than on the occurrence of side effects, time to
relief, and increased out-of-pocket costs.
This research suggests that patients with GERD may prefer
quite different treatments depending on the levels of side effects,
incidence of sleeping disorders, daytime disorders, dietary issues,
dosing, and cost. Sometimes, fairly general states of health and
general treatment have been used when conducting economic
analyses of GERD and other health problems [49]. The findings
from this study based on specific treatments may inform
researchers on the most important aspects of GERD when
investigating the reactions of patients in studies pertaining to
the economic evaluation of treatments. For example, measuring
economic and other benefits based on incidence of GERD during
sleep or reduction of side effects may lead to greater insights
than using general measures such as healthy days, remission,
relapsing, and quality of life without detailed definitions.
Results from retrospective studies of patients with GERD report
poor adherence and persistence rates with short median durations
of therapy of 241 days for PPIs and 159 days for H2 receptor
antagonists [13]. Findings from randomized controlled studies in
the United Kingdom have shown that higher levels of satisfaction
with GERD treatment translate into increased willingness to
continue therapy and significantly longer times to discontinuation
[14]. By understanding patients’ preferences for specific attributes
of GERD treatment, health care providers can identify a treatment
approach for each individual patient that may lead to improved
control and, ultimately, better outcomes through improved com-
pliance [15,16]. Our findings of significant differences between
groups indicate that there may be advantages to treating patients
on the basis of their group membership in addition to their
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 8 8 – 5 9 8596symptoms. Clinicians, formulary committees, managed care
organizations, manufacturers, and insurance providers can use
the information derived from this study to quantitatively estimate
the value of a treatment with specific characteristics.
Limitations
The findings are likely a reasonable reflection of preferences for
the GERD patient population in Canada. The sample was drawn
from the 17 clinical trial centers across the country and was
similar to the Canadian census population with respect to sex
(z ¼ 0.603, P o 0.01), household income distribution (w2 ¼ 4.85, P ¼
0.05), and percentage of unemployed individuals (z ¼ 0.78,
Po 0.01) [50].
The attribute levels for the DCE were selected on the basis of
expert judgment and findings from the focus groups. In general,
those attribute levels were understandable by the respondents
and represented the realistic range of alternatives that could face
patients. When calculating the WTP, however, it was found that
patients may be willing to pay more than the highest level of
monthly cost for the most beneficial levels of some attributes,
especially for reduction of side effects, and for some combina-
tions of attribute levels. While we decided to not extrapolate
beyond the US $70 maximum cost level that was included in this
survey, we would consider increasing slightly the highest
monthly cost levels if we were to repeat this study. Nonetheless,
US $70 is higher than the cost of the treatments that were on the
market at the time of the research and increasing the pricing
much beyond the relevant range may decrease respondent
attention to the price attribute [51].
Utility balance was not imposed on the experimental design.
While utility balance has been included as an important criterion
for DCE design, in addition to orthogonality, D-efficiency, and
level balance, it has come under substantial criticism lately
[52,53], with Huber stating [52], ‘‘Utility balance has failed as a
design criterion.’’
Primary design concerns are that respondents understand the
task involved in the DCE questions, can adequately answer the
questions, consider the attributes and levels presented in each
choice task, do not lose focus through boredom, and complete all
the tasks. Evolving general guidelines, rather than rules, tend to
influence the development of DCE—and those evolve. Many DCEs
have between three to five alternatives per choice task and some
have upwards of 20—we chose three as a design that would
provide a reasonable quantity of data while not overburdening
the cognitive abilities of respondents when considering each
choice task. The effects, if any, of respondent fatigue have
become an increasingly important and evolving topic for DCE
researchers. Rolfe and Bennett [54] found that respondents were
able to more easily analyze the choice sets and to make decisions
when presented with three alternatives per choice set, rather
than two, and that there was greater serial nonparticipation and
higher rate of ‘‘not sure’’ responses in the two alternative
formats. The DCE design included 14 choice tasks, with the
common range being 12 to 16 tasks. Overall, the design character-
istics of this study fall within the general range of suggested
parameters for DCE designs.
As is the case with all surveys, our results and conclusions are
based on the attributes and levels included in this DCE. We
followed generally accepted standards [55] for development of
the attributes and levels based on the initial qualitative research,
literature search, and expert judgment provided.
The effect of including a cost attribute in the choice set has
been discussed in the literature [56,57]. Pedersen et al. [58] found
that inclusion of a cost attribute tended to affect choice behavior
and the preference structure. Essers et al. [59] compared cost and
noncost DCEs and found that the similar estimated preferencestructure held in both cases, with cost being a significant
attribute in the cost half of the study. Campbell et al. [51]
concluded that it is important to ensure that cost levels fall
within the relevant range for consideration and are behaviorally
relevant or respondents may not attend to the attribute or some
of the levels. The presentation of choice sets not including the
cost/price attribute may present unrealistic and alien choice
situations to subjects. Bryan et al. [60] found the cost variable
to be nonsignificant when used in a study of magnetic resonance
imaging where cost is typically free in the United Kingdom—WTP
was not part of that study. Also, of course, the calculation of WTP
would be forced outside of the trade-off environment of the DCE,
which may impact the WTP estimates. The positioning of the
cost attribute within each choice alternative may have had an
effect on preferences, but that was not investigated in this
research.
Conducting WTP studies using DCEs with cost treated as a
categorical variable provides the option to investigate nonlinear
price effects [47]. Kinks in price curves provide important infor-
mation to suppliers of pharmaceutical products for pricing their
products and to policymakers. In addition, this approach to the
price attribute can show other pricing effects, such as was found
here where the PWU of CAN $30 per month was slightly, although
not statistically significantly, higher than was the PWU of CAN $3
per month; perhaps reflecting a perceptual relationship between
price and quality.
Future research should address the heterogeneity of choice
and preferences of this and other health care markets. We did not
segment the sample on the basis of preference coefficients
whereas patients with GERD may have a broad range of prefer-
ences for treatments and the constituent attributes. The HB
coefficients for each respondent could be used to identify several
segments of patients that have similar treatment preferences
within the segments but significantly diverse across those seg-
ments. This approach can add significant insight for providing
treatments more conducive to the needs of segments of patients.Conclusions
GERD and GERD-like symptoms affect a large number of
people—about one-third of the Canadian population [1]—and
are associated with a high burden of illness; more than a billion
dollars are spent annually for over-the-counter medications for
GERD [18]. This study provides information to improve our
understanding of these patient populations and their preferences
and assists with prescribing the best treatment to manage their
GERD symptoms.
Managing patient care to alleviate their greatest concerns and
support their need for health improvement is paramount in
health care. This research indicated that patients with GERD
are most concerned about the side effects of treatment. We can
see from Figure 2 that the PWU for severe side effects is
substantially lower than for moderate side effects. Typically,
health care professionals should ensure that patients receive
treatments that do not threaten them with severe side effects.
Patients were next most concerned with the degree of symptom
relief, both when sleeping and during the daytime—more so than
dietary changes, timing of medication, and out-of-pocket costs.
The implications for health care professionals is to first
manage treatment such that side effects are minimized and do
not exceed a moderate level and then to manage the GERD with
the most effective therapy for symptom relief when sleeping and
then during the day. This is consistent with current clinical
guidelines recommending long-term treatment with PPIs at the
lowest dose sufficient to control symptoms. Our findings suggest
that this approach to treatment would contribute to improved
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 8 8 – 5 9 8 597medication compliance, effective management of GERD, and
reduce lost productivity and workdays missed from GERD-
related symptoms.
Respondents were willing to pay significant additional fees for
easing the personal challenges of GERD, especially for a reduction
in side effects and episodes of GERD during sleep. The WTP varies
for other attributes and would be higher for treatments com-
posed of enhanced combinations of attributes. Within the reim-
bursement context in Canada, where medications costs of PPIs
range from approximately US $10 to US $64 on formularies, and
as much as US $140 for 30 tablets as quoted on an Internet
pharmacy, this falls within the range of what patients are
currently paying for their GERD medications. However, this
research illustrates the potential differences between actual
prices and prices based on the value ascribed to treatments by
patients with GERD.
This research has explained the value of using DCEs to
identify patients’ preferences for GERD treatments and estimat-
ing WTP based on simulations and sensitivity analyses. DCEs can
provide valuable direction to physicians when managing GERD
symptoms, to companies when designing pharmaceuticals to
encourage long-term treatment adherence, and to policymakers
when considering the value of treatments to the population.
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